Farmacinių atliekų šalinimas, UAB - financials and debts
Company age: 15 y. 7 mo.
Farmacinių atliekų šalinimas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 86,503 | 86,233 | 102,915 | 159,637 | 197,857 | 178,852 | 242,612 | 180,465 |
| Profit before tax | - | - | - | 71,340 | 42,514 | - | - | - |
| Net profit | 17,556 | 27,484 | 39,275 | 67,773 | 40,382 | 50,900 | 74,361 | 18,553 |
| Equity | 81,793 | 109,278 | 148,553 | 216,326 | 256,708 | 287,632 | 361,993 | 380,546 |
| Liabilities | 9,601 | 11,593 | 15,400 | 17,536 | 39,017 | 55,120 | 42,415 | 22,860 |
| Non-current assets | 5,401 | 3,854 | 4,530 | 17,614 | 20,519 | 12,793 | 16,152 | 17,630 |
| Current assets | 85,993 | 116,910 | 159,331 | 216,248 | 274,822 | 329,959 | 388,256 | 384,700 |
| Total assets | 91,394 | 120,764 | 163,861 | 233,862 | 295,341 | 342,752 | 404,408 | 402,330 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 25,091 | 35,265 | 31,012 |
| Social insurance contributions | - | - | - | - | - | 6,017 | 6,809 | 11,283 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +103.5% | -0.3% | +19.3% | +55.1% | +23.9% | -9.6% | +35.6% | -25.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 19.2% | 22.8% | 24.0% | 29.0% | 13.7% | 14.9% | 18.4% | 4.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 21.5% | 25.2% | 26.4% | 31.3% | 15.7% | 17.7% | 20.5% | 4.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 20.3% | 31.9% | 38.2% | 42.5% | 20.4% | 28.5% | 30.7% | 10.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | 44.7% | 21.5% | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 11,796 | 12,319 | 18,712 | 31,404 | 29,678 | 25,250 | 34,659 | 26,091 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Farmacinių atliekų šalinimas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-16 | 2026-08-16 | 3.77 |
| 2026-07-27 | 2026-08-14 | 3.77 |
| 2026-07-26 | 2026-07-26 | 1255.45 |
| 2026-07-23 | 2026-07-25 | 1259.22 |
| 2026-07-19 | 2026-07-22 | 1255.45 |
| 2026-07-16 | 2026-07-17 | 1255.45 |
| 2026-05-03 | 2026-05-12 | 5.38 |
| 2026-04-24 | 2026-04-29 | 5.38 |
| 2026-04-20 | 2026-04-23 | 1611.99 |
| 2026-03-27 | 2026-03-27 | 1167.29 |
| 2026-03-17 | 2026-03-25 | 1167.29 |
| 2026-01-21 | 2026-01-22 | 1132.19 |
| 2026-01-16 | 2026-01-20 | 1129.72 |
| 2025-12-16 | 2025-12-21 | 1093.96 |
| 2025-11-18 | 2025-11-23 | 1195.85 |
| 2025-10-16 | 2025-10-16 | 344.61 |
| 2025-09-16 | 2025-09-21 | 1020.83 |
| 2025-08-28 | 2025-08-29 | 1037.02 |
| 2025-08-19 | 2025-08-26 | 1037.02 |
| 2025-07-24 | 2025-08-18 | 3.04 |
| 2025-07-16 | 2025-07-23 | 693.73 |
| 2025-05-16 | 2025-05-19 | 621.47 |
| 2025-04-16 | 2025-04-21 | 1257.04 |
| 2025-03-18 | 2025-03-25 | 1276.57 |
| 2025-03-03 | 2025-03-03 | 1181.39 |
| 2025-02-18 | 2025-02-26 | 1181.39 |
| 2025-01-22 | 2025-01-23 | 955.47 |
| 2025-01-16 | 2025-01-21 | 949.97 |
| 2024-12-17 | 2024-12-20 | 905.32 |
| 2024-11-18 | 2024-11-25 | 855.70 |
| 2024-10-29 | 2024-11-17 | 7.89 |
| 2024-10-24 | 2024-10-27 | 7.89 |
| 2024-10-16 | 2024-10-23 | 863.29 |
| 2024-09-17 | 2024-09-25 | 889.40 |
| 2024-08-19 | 2024-08-26 | 967.74 |
| 2024-07-24 | 2024-08-18 | 10.37 |
| 2024-07-16 | 2024-07-23 | 864.27 |
| 2024-06-18 | 2024-06-26 | 1005.05 |
| 2024-05-16 | 2024-05-26 | 1200.25 |
| 2024-04-24 | 2024-05-15 | 7.51 |
| 2024-04-23 | 2024-04-23 | 1224.84 |
| 2024-04-16 | 2024-04-22 | 1217.33 |
| 2024-03-18 | 2024-03-25 | 1099.41 |
| 2024-02-19 | 2024-02-26 | 1008.04 |
| 2024-01-23 | 2024-02-18 | 38.59 |
| 2024-01-16 | 2024-01-22 | 31.14 |
| 2023-11-22 | 2023-11-23 | 110.51 |
| 2023-11-16 | 2023-11-21 | 1075.56 |
| 2023-10-25 | 2023-10-25 | 1785.64 |
| 2023-10-17 | 2023-10-24 | 1777.86 |
| 2023-09-27 | 2023-09-27 | 67.35 |
| 2023-09-26 | 2023-09-26 | 693.22 |
| 2023-09-18 | 2023-09-25 | 806.41 |
| 2023-08-17 | 2023-08-28 | 781.13 |
| 2023-07-27 | 2023-07-27 | 28.80 |
| 2023-07-26 | 2023-07-26 | 228.39 |
| 2023-07-24 | 2023-07-25 | 758.46 |
| 2023-07-18 | 2023-07-23 | 752.95 |
| 2023-06-16 | 2023-06-25 | 781.29 |
| 2023-05-16 | 2023-05-23 | 748.60 |
| 2023-04-18 | 2023-04-20 | 762.58 |
| 2023-03-16 | 2023-03-19 | 781.29 |
| 2023-02-17 | 2023-02-23 | 650.46 |
| 2023-01-20 | 2023-01-25 | 599.52 |
| 2023-01-17 | 2023-01-19 | 594.91 |
| 2022-12-16 | 2022-12-20 | 513.53 |
| 2022-11-21 | 2022-11-23 | 686.52 |
| 2022-11-17 | 2022-11-18 | 686.52 |
| 2022-10-28 | 2022-11-16 | 5.14 |
| 2022-10-18 | 2022-10-25 | 681.38 |
| 2022-09-16 | 2022-09-25 | 681.38 |
| 2022-08-23 | 2022-08-28 | 596.79 |
| 2022-07-18 | 2022-07-21 | 268.08 |
| 2022-06-16 | 2022-06-22 | 540.01 |
| 2022-05-17 | 2022-05-18 | 193.69 |
| 2022-04-19 | 2022-04-21 | 110.59 |
| 2022-03-16 | 2022-03-27 | 407.42 |
| 2022-02-17 | 2022-02-24 | 680.76 |
| 2022-01-31 | 2022-02-16 | 2.60 |
| 2022-01-18 | 2022-01-26 | 72.36 |
| 2021-11-16 | 2021-11-23 | 516.03 |
| 2021-11-08 | 2021-11-15 | 1.43 |
| 2021-10-18 | 2021-10-25 | 355.70 |
| 2021-09-16 | 2021-09-26 | 397.89 |
Farmacinių atliekų šalinimas - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Farmacinių atliekų šalinimas is: 2,406 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-02 | 2026-09-02 | 2406.19 |
| 2026-08-31 | 2026-09-01 | 2890.55 |
| 2026-08-28 | 2026-08-30 | 3917.55 |
| 2026-08-26 | 2026-08-27 | 587.41 |
| 2026-08-18 | 2026-08-25 | 587.09 |
| 2026-08-16 | 2026-08-17 | 3036.5 |
| 2026-08-07 | 2026-08-15 | 150.25 |
| 2026-08-02 | 2026-08-06 | 150.01 |
| 2026-07-20 | 2026-08-01 | 151.33 |
| 2026-07-02 | 2026-07-19 | 2.8 |
| 2026-06-28 | 2026-07-01 | 2071.77 |
| 2026-05-31 | 2026-06-01 | 15.89 |
| 2026-04-23 | 2026-04-23 | 401.0 |
| 2026-04-22 | 2026-04-22 | 645.46 |
| 2026-04-17 | 2026-04-21 | 3341.26 |
| 2026-03-29 | 2026-03-30 | 159.34 |
| 2025-12-17 | 2025-12-18 | 566.29 |
| 2025-11-02 | 2025-11-14 | 169.39 |
| 2025-10-30 | 2025-11-01 | 868.42 |
| 2025-10-02 | 2025-10-06 | 132.47 |
| 2025-09-26 | 2025-10-01 | 132.37 |
| 2025-09-17 | 2025-09-25 | 672.96 |
| 2025-09-02 | 2025-09-16 | 387.02 |
| 2025-09-01 | 2025-09-01 | 2287.02 |
| 2025-08-30 | 2025-08-31 | 2282.58 |
| 2025-08-21 | 2025-08-29 | 705.58 |
| 2025-08-19 | 2025-08-20 | 700.86 |
| 2025-08-01 | 2025-08-18 | 448.12 |
| 2025-07-31 | 2025-07-31 | 447.9 |
| 2025-07-30 | 2025-07-30 | 448.29 |
| 2025-07-29 | 2025-07-29 | 430.87 |
| 2024-11-26 | 2024-11-26 | 290.86 |
| 2024-11-24 | 2024-11-25 | 290.62 |
| 2024-11-21 | 2024-11-23 | 290.46 |
| 2024-11-17 | 2024-11-20 | 288.3 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Farmaciniu atlieku šalinimas, UAB (code 302591932) is a Private Limited Liability Company engaged in materials recovery. In 2025, the company generated revenue of €180.5K and net profit of €18.6K, with a profit margin of 10.3%. Revenue declined by 25.6% year on year after a stronger 2024, when turnover reached €242.6K and net profit was €74.4K. In 2023, revenue stood at €178.9K and net profit at €50.9K, showing that the business has remained profitable across the three-year period, although 2025 was clearly weaker than the prior year. Total assets in 2025 were €402.3K, supported by equity of €380.5K and liabilities of €22.9K. The balance sheet remains highly equity-based, with an equity ratio of 94.6% and debt-to-equity of 0.06. Asset turnover was 0.45x, while return on equity was 4.9% and return on assets 4.6%. Revenue per employee was €30.1K and profit per employee was €3.1K, indicating a modest operating scale.